Keymed Biosciences Inc. (HKG:2162)

Hong Kong · Delayed Price · Currency is HKD

57.50

+1.60 (2.86%)

Jun 18, 2026, 4:08 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
R&D and Commercialisation of Pharmaceutical Products	716.31M	428.12M	354.10M	100.06M	110.27M
R&D and Commercialisation of Pharmaceutical Products Growth	67.31%	20.91%	253.87%	-9.26%	-
Total	716.31M	428.12M	354.10M	100.06M	110.27M
Total Growth	67.31%	20.91%	253.87%	-9.26%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States of America	393.67M	335.01M	-	-	-
United States of America Growth	17.51%	-	-	-	-
Mainland China	322.17M	36.97M	903.00K	100.06M	110.27M
Mainland China Growth	771.35%	3994.57%	-99.10%	-9.26%	-
United Kingdom	474.00K	56.14M	-	-	-
United Kingdom Growth	-99.16%	-	-	-	-
Overseas	-	-	353.19M	-	-
Total	716.31M	428.12M	354.10M	100.06M	110.27M
Total Growth	67.31%	20.91%	253.87%	-9.26%	-